EP300
EP300 (EP300 lysine acetyltransferase, also known as p300 and KAT3B) is a histone acetyltransferase that acts as a transcriptional co-activator. It regulates gene expression through chromatin remodelling and was first identified as an adenovirus E1A-binding protein. Browse Assay Genie's current range of EP300 research reagents below, or read on for the biology behind the target.
EP300 is the adenovirus E1A-associated cellular p300 transcriptional co-activator. It functions as a histone acetyltransferase (EC 2.3.1.48), regulating transcription via chromatin remodelling, and it is important in cell proliferation and differentiation. It mediates cAMP-dependent gene regulation by binding specifically to phosphorylated CREB protein, and it also acts as a co-activator of HIF1A (hypoxia-inducible factor 1 alpha), contributing to the stimulation of hypoxia-induced genes such as VEGF.
The EP300 protein is annotated in UniProt as histone acetyltransferase p300 and is found in the cytoplasm, the nucleus and on chromosomes. In HGNC the EP300 gene sits in the groups of zinc fingers ZZ-type, lysine acetyltransferases and bromodomain-containing proteins. The mouse ortholog is Ep300.
The symbol reflects the discovery of p300 through its interaction with viral proteins. The previous name, E1A binding protein p300, refers to its binding to the adenovirus E1A protein, and it may be involved in the transforming capacity of E1A. During HIV-1 infection, EP300 is recruited by the viral protein Tat, where it regulates Tat's transactivating activity and may help induce chromatin remodelling of proviral genes. Defects in the EP300 gene are a cause of Rubinstein-Taybi syndrome and may also play a role in epithelial cancer.
EP300 acetylates histones and remodels chromatin, making it a central subject for studies of transcriptional regulation.
As a co-activator of HIF1A, EP300 supports the induction of hypoxia-responsive genes such as VEGF.
Defects in the EP300 gene cause Rubinstein-Taybi syndrome, so the protein is studied in developmental disorders.
EP300 may contribute to epithelial cancer and interacts with adenovirus E1A and HIV-1 Tat, linking it to oncogenesis and viral transcription.
EP300 is a histone acetyltransferase and transcriptional co-activator. It regulates transcription through chromatin remodelling and is important in cell proliferation and differentiation. It binds phosphorylated CREB to mediate cAMP-gene regulation and co-activates HIF1A to stimulate hypoxia-induced genes such as VEGF.
EP300 is also called p300 and KAT3B, and its UniProt protein name is histone acetyltransferase p300. A previous name was E1A binding protein p300, reflecting its binding to adenovirus E1A. The HGNC full name is EP300 lysine acetyltransferase.
Defects in the EP300 gene are a cause of Rubinstein-Taybi syndrome and may also play a role in epithelial cancer. A mouse ortholog, Ep300, exists; check the datasheet of any product for its validated reactivity.
Other targets with EP-prefixed symbols, including hypoxia-related and receptor proteins, with products at Assay Genie.
Gene and protein annotations from HGNC, NCBI Gene and UniProt Q09472; product specifications from Assay Genie datasheets.